The present and future disease burden of hepatitis <scp>C</scp> virus (<scp>HCV</scp>) infections with today's treatment paradigm – volume 2Angelos Hatzakis, E. Nurmukhametova, Vladimir Chulanov et al.|Journal of Viral Hepatitis|2015Cited by 125
A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung CancerDaniel A. Goldstein, Alona Zer, Salomon M. Stemmer et al.|JNCI Journal of the National Cancer Institute|2017Cited by 102
Historical epidemiology of hepatitis C virus (<scp>HCV</scp>) in select countries – volume 2V A Saraswat, N. Mamonova, Н. П. Блохина et al.|Journal of Viral Hepatitis|2015Cited by 93
Strategies to manage hepatitis <scp>C</scp> virus (<scp>HCV</scp>) infection disease burden – volume 2Edward Gane, E. Nurmukhametova, Vladimir Chulanov et al.|Journal of Viral Hepatitis|2015Cited by 54